Last updated: 7 June 2024 at 5:40pm EST

Elizabeth Barrett Net Worth




The estimated Net Worth of Elizabeth A. Barrett is at least 30.4 百万$ dollars as of 31 January 2023. Ms. Barrett owns over 18,333 units of UroGen Pharma Ltd stock worth over 4,511,603$ and over the last 6 years she sold URGN stock worth over 0$. In addition, she makes 25,900,800$ as President、 Chief Executive Officer、 Director at UroGen Pharma Ltd.

Ms. Barrett URGN stock SEC Form 4 insiders trading

Elizabeth has made over 11 trades of the UroGen Pharma Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 18,333 units of URGN stock worth 253,179$ on 31 January 2023.

The largest trade she's ever made was exercising 105,689 units of UroGen Pharma Ltd stock on 3 January 2022 worth over 1,459,565$. On average, Elizabeth trades about 20,278 units every 62 days since 2019. As of 31 January 2023 she still owns at least 326,691 units of UroGen Pharma Ltd stock.

You can see the complete history of Ms. Barrett stock trades at the bottom of the page.





Elizabeth Barrett biography

Elizabeth Barrett is President, Chief Executive Officer, Director of the Company. Before joining us Ms. Barrett served as the Chief Executive Officer of Novartis Oncology and as a member of the Executive Committee of Novartis since February 2018. Prior to that, Ms. Barrett served at Pfizer Inc. in various capacities, most recently as the Global President of Oncology, and before that as Pfizer’s Regional President of US Oncology Business Unit since March 2009. Prior to Pfizer, she was Vice President and General Manager of the Oncology Business Unit at Cephalon Inc. Ms. Barrett received a Bachelor of Science in Business Administration from the University of Louisiana in Lafayette, Louisiana and a Master’s in Business Administration-Marketing from St. Joseph’s University in Philadelphia, Pennsylvania. Our Board believes Ms. Barrett’s leadership of both large organizations and growing businesses qualifies her to serve on our board of directors.

What is the salary of Elizabeth Barrett?

As the President、 Chief Executive Officer、 Director of UroGen Pharma Ltd, the total compensation of Elizabeth Barrett at UroGen Pharma Ltd is 25,900,800$. There are no executives at UroGen Pharma Ltd getting paid more.



How old is Elizabeth Barrett?

Elizabeth Barrett is 57, she's been the President、 Chief Executive Officer、 Director of UroGen Pharma Ltd since 2019. There are 8 older and 7 younger executives at UroGen Pharma Ltd. The oldest executive at UroGen Pharma Ltd is Stuart Holden, 77, who is the Independent Director.

What's Elizabeth Barrett's mailing address?

Elizabeth's mailing address filed with the SEC is 210 EAST GRAND AVENUE, , SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at UroGen Pharma Ltd

Over the last 7 years, insiders at UroGen Pharma Ltd have traded over 8,740,363$ worth of UroGen Pharma Ltd stock and bought 33,940 units worth 791,524$ . The most active insiders traders include Ran NussbaumArie BelldegrunKathryn E Falberg. On average, UroGen Pharma Ltd executives and independent directors trade stock every 31 days with the average trade being worth of 214,027$. The most recent stock trade was executed by Mark Schoenberg on 10 June 2024, trading 10,000 units of URGN stock currently worth 138,100$.



What does UroGen Pharma Ltd do?

urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.



Complete history of Ms. Barrett stock trades at UroGen Pharma Ltd、Allogene Therapeutics Inc

インサイダー
取引
取引
合計金額
Elizabeth A. Barrett
Chief Executive Officer
オプション行使 190,480$
31 Jan 2023
Elizabeth A. Barrett
Chief Executive Officer
オプション行使 141,531$
31 Jan 2022
Elizabeth A. Barrett
Chief Executive Officer
オプション行使 1,028,354$
3 Jan 2022
Elizabeth A. Barrett
Chief Executive Officer
オプション行使 248,802$
3 Jan 2021
Elizabeth A. Barrett
Chief Executive Officer
購入する 185,000$
14 Dec 2020
Elizabeth A. Barrett
Chief Executive Officer
オプション行使 1,212,078$
4 Dec 2020
Elizabeth A. Barrett
Chief Executive Officer
オプション行使 857,474$
12 May 2020
Elizabeth A. Barrett
Chief Executive Officer
オプション行使 3,369,333$
3 Jan 2020
Elizabeth A. Barrett
Chief Executive Officer
購入する 210,840$
21 Nov 2019
Elizabeth A. Barrett
Chief Executive Officer
購入する 209,160$
20 Nov 2019
Elizabeth A. Barrett
Chief Executive Officer
購入する 40,248$
15 Nov 2019


UroGen Pharma Ltd executives and stock owners

UroGen Pharma Ltd executives and other stock owners filed with the SEC include: